During chemotherapy, blood tumor markers are often checked cycle by cycle. When a number that had been falling steadily rises once, many people immediately wonder whether the cancer has become resistant to the drug. In clinical practice, however, terms like resistance or disease progression are not attached to a single number. They are conclusions drawn after several different lines of evidence are laid side by side.
The first is imaging. Whether a treatment is still working is usually judged on CT or MRI by measuring changes in known lesions and looking for new ones. Standardized rules such as RECIST are commonly used, and classifying a scan as progression generally requires growth beyond a defined threshold or the appearance of new disease. Regimens are rarely changed on a blood value alone; more often the discussion is about whether the next scan should be moved earlier.
The second is the trend in the number itself. Direction and slope carry more information than any single value. It matters whether the rise has repeated across two or more draws, whether it is a small drift or a doubling, and how far the value sits above its previous low point. Results can also shift when the laboratory or the assay kit changes, so testing in the same place makes comparison more reliable.
The third is everything in the body that is not cancer. Bile duct narrowing or a blocked stent, cholangitis and other infections, inflammation, and fluctuating liver function can all push markers up. Smoking and some benign conditions influence certain markers as well. CA 19-9 is a particular case: people who are Lewis antigen negative may show little or no elevation even with active disease, which limits its usefulness for follow-up in that group. This is why the same rise is read differently depending on whether jaundice, fever, or abdominal pain is present.
The fourth is timing. Values can move depending on where in the cycle blood was drawn, and transient early rises that later settle have been described. Drawing blood at a similar point in each cycle reduces this noise.
A useful sequence before the next test: list every past value with its date so the trend is visible at a glance; note how you felt on each draw day, including fever, chills, urine color, yellowing of the eyes or skin, pain, and weight; check whether the testing facility ever changed; confirm the date of the next scan and any procedures scheduled in between; and write down the questions you want to ask, such as how the clinician reads the current number, whether imaging should be brought forward, what the next options would be if progression is confirmed, when tissue or blood based genomic testing might be considered, and whether a clinical trial could apply.
While waiting, yellowing of the eyes or skin, dark urine, fever with chills, a sudden increase in pain, or an inability to eat are reasons to contact the care team rather than wait for the scheduled visit. Such changes may need treatment in their own right, and they sometimes explain the rising number.
Finally, even confirmed progression does not mean the end of treatment. Switching to another line of therapy, adding local treatment, prioritizing symptom control, or exploring a clinical trial each rest on different conditions, including overall fitness, organ function, and prior therapy. The single number in hand today is one ingredient among several in that decision.
This article is general information and does not replace medical care for any individual. Please discuss the interpretation of your test results and any treatment decisions with your own healthcare team.